AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 1 - (NewsRx.com & NewsRx.net) -- A team of researchers from France and the U.S. presented at the 2004 annual meeting of the American Society of Clinical Oncology follow-up data on an autologous hemoderivative vaccine administered to breast cancer patients.
E. Garcia-Giralt, E. Lasalvia-Prisco, and colleagues at the Hartmann Cancer Center in Neuilly, France, and at PharmaBlood, North Miami Beach, Florida, U.S., had told the conference last year about "a vaccination procedure with an autologous hemoderivative (AH) that in solid tumors, including breast cancer, inhibited the progressive disease condition, elicited delayed type hypersensibility (DTH), and induced a tumor stroma modification in responder patients." The researchers also had published this work (E. Lasalvia-Prisco et al., Cancer Biol Ther, 2003).
This year their report was an account of the disease in responder vaccinated patients and DTH evolution in those patients. Of 30 patients (age 38-72) with metatastic, chemotherapy-resistant breast cancer who had received the AH vaccine, 11 were found to be responders (stable disease + partial remission) with a "DTH-positive response elicited by AH (= 5 mm)" after 6 months.
"When progressive disease reappeared, a second vaccination with a second AH was performed. Follow-up of these 11 responder patients was analyzed ...
Source: HighBeam Research, Follow-up data presented on autologous hemoderivative vaccine.